Select 2023 EULAR & 2024 KDIGO Lupus Recommendations: Considerations for Your Patient Population

July 18, 2024

Thursday, July 18, 2024 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Lupus is a disease of progressive, and often irreversible, organ damage. It is more common in women and non-white populations. Factors such as long-term use of corticosteroids, high disease activity and flares may increase the risk of organ damage, while lupus nephritis may lead to significant chronic kidney disease, and potentially end stage kidney disease. Recently updated EULAR and KDIGO guidelines reflect up-to-date evidence and expert consensus and may be applied to your populations to improve patient outcomes, including minimizing toxicities, flares and risk of organ damage progression.

Learning Objectives

By the end of the program, you will be able to:

  • Discuss the clinical manifestations of lupus.
  • Review select 2023 EULAR and 2024 KDIGO recommendations.
  • Apply the recommendations (patient case study).

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email

Course summary
Course opens: 
Course expires: 
Event starts: 
07/18/2024 - 2:00pm EDT
Event ends: 
07/18/2024 - 3:00pm EDT


Saira Z. Sheikh, MD
Linda C. Sewell Distinguished Professor of Medicine
Director, UNC Rheumatology Lupus Clinic
Director, Clinical Trials Program, UNC Thurston Arthritis Research Center
University of North Carolina, Chapel Hill, NC


Please login or register to take this course.

Required Hardware/software

AMCP Learn utilizes the GoTo Webinar platform for live webinars. Before joining, be sure to check system requirements to avoid any connection issues. If you experience technical issues joining the webinar, please email